Armistice Capital, LLC Acquires 8.27% Stake in Vivos Therapeutics, Inc. (VVOS)

On May 15, 2026, Armistice Capital, LLC and its managing member, Steven Boyd, filed a Schedule 13G regarding their holdings in Vivos Therapeutics, Inc. (VVOS). The filing reveals that the reporting persons have acquired a beneficial ownership of 1,115,859 shares of common stock, representing an 8.27% stake in the company. This position was established as of the event date on March 31, 2026. Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Under the investment management agreement, Armistice Capital exercises shared voting and dispositive power over the securities. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This initial 13G filing marks a significant new position for the investment firm in the Littleton, Colorado-based medical technology company.